The purpose of this prospective observational investigation was to determine whether the frequency of premenstrual dysphoric disorder (PMDD) and the severity of PMDD symptoms differ between women with epilepsy and controls without epilepsy and whether there exists a relationship between the severity of PMDD symptoms and some epileptic, antiepileptic drug, and reproductive endocrine features. The results suggest that epilepsy, antiepileptic drug levels, ovulatory status, and hormone levels and ratios may all influence PMDD in women with epilepsy. PMDD severity scores may be greater in people with right-sided than in those with left-sided epilepsy, and in people with temporal than in those with nontemporal epileptic foci. PMDD severity scores may be greater with anovulatory cycles, and scores may correlate negatively with midluteal serum progesterone levels and positively with midluteal estradiol/progesterone ratios. Mood score may vary with particular antiepileptic drugs, favoring carbamazepine and lamotrigine over levetiracetam. PMDD severity scores may correlate directly with carbamazepine levels, whereas they correlate inversely with lamotrigine levels.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yebeh.2011.05.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psychological stress dysfunction in women with premenstrual syndrome.
Heliyon
November 2024
Mental Health Education Center, Xidian University, Xi'an, China.
Premenstrual syndrome (PMS) encompasses a range of emotional, physiological, and behavioral symptoms that occur during the luteal phase of the menstrual cycle (MC) and resolve with the onset of menstruation. These symptoms, which can include fatigue, physical pain, anxiety, irritability, and depression, significantly affect women's daily lives and overall well-being. In severe cases, PMS can progress to premenstrual dysphoric disorder (PMDD), profoundly impairing quality of life.
View Article and Find Full Text PDFDeveloping a Mood and Menstrual Tracking App for People With Premenstrual Dysphoric Disorder: User-Centered Design Study.
JMIR Form Res
December 2024
School of Computer Science, Cardiff University, Cardiff, United Kingdom.
Background: People with premenstrual dysphoric disorder (PMDD) experience a range of symptoms that increase and decline as a result of the natural hormonal fluctuations of the menstrual cycle. For the diagnosis of PMDD, symptom severity needs to be recorded daily for at least two symptomatic cycles. In recent years, the rise in interest in Femtech (tools and technology developed to address women's health issues) has resulted in a large quantity of "period-tracking apps" being developed and downloaded.
View Article and Find Full Text PDFDisseminating Premenstrual Dysphoric Disorder Information on TikTok: A Content Analysis.
Health Commun
December 2024
Perelman School of Medicine, University of Pennsylvania.
Premenstrual dysphoric disorder (PMDD) is characterized as an extreme form of premenstrual syndrome (PMS) in which a combination of severe mood, somatic, and cognitive symptoms present one to two weeks prior to the onset of menstruation. As people increasingly turn to social media, specifically TikTok, to gain information about health-related topics and information, discourse about this taboo chronic condition has increased. Sensitized by concepts from the theory of communicative disenfranchisement (TCD), our two-pronged methodological approach includes a content analysis of TikTok videos ( 97) that discuss PMDD symptomology, treatment, and a thematic analysis of disenfranchising talk associated with PMDD.
View Article and Find Full Text PDFPvuII-ESR1 gene polymorphism in premenstrual dysphoric disorder in South Indian women.
Indian J Psychiatry
October 2024
Department of Biochemistry, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India.
Background: Premenstrual dysphoric disorder (PMDD) is a condition that affects nearly 3-9% of the women in the reproductive age during the luteal phase of each menstrual cycle characterized by symptoms varying in severity and affecting the quality of life. Earlier research studies conducted have reported independent relationships between PvuII-ESR1-polymorphism and psychological traits in PMDD and risk for cognitive, behavioral, and affective symptoms. However, as the studies are few in number and the results are not consistent, there is a need for our study to link between the PvuII-ESR1gene and PMDD.
View Article and Find Full Text PDFNeuroactive steroid levels are elevated in the follicular phase and predict premenstrual depression and anxiety symptom severity in women with menstrually related mood disorder.
Arch Womens Ment Health
November 2024
Neuroendocrine Unit, Massachusetts General Hospital, 50 Staniford St., Suite 750B, Boston, MA, 02114, USA.
Article Synopsis
- Menstrually related mood disorder (MRMD) is characterized by severe emotional symptoms occurring in the late luteal phase of the menstrual cycle, which may be linked to low levels of the neuroactive steroid allopregnanolone due to lesser conversion from progesterone.
- In a study with nine women with MRMD and fourteen healthy controls, MRMD was diagnosed using the DSM-5 criteria, and symptoms of depression and anxiety, as well as plasma neuroactive steroid levels, were assessed at different phases of the menstrual cycle.
- Results showed that while women with MRMD had higher allopregnanolone levels in the mid-follicular phase, they experienced greater depression severity only in the late luteal phase, suggesting a
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!